Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18209464 | 0.86 | TDP1 (0.66) | ALDH1A1TDP1SMN1; SMN2TTRTSHR | |
| SCHEMBL2559748 | 0.85 | SMN1; SMN2 (0.51) | ALDH1A1L3MBTL1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL15332447 | 0.85 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1TDP1SMN1; SMN2TTR | |
| SCHEMBL29956255 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TDP1SMN1; SMN2TTRTSHR | |
| SCHEMBL2560660 | 0.81 | ALDH1A1 (0.78) | ALDH1A1TDP1SNCASMN1; SMN2MAPK1 | |
| SCHEMBL15329485 | 0.81 | ALDH1A1 (0.65) | ALDH1A1L3MBTL1SNCASMN1; SMN2MAPK1 | |
| SCHEMBL15332288 | 0.81 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRPOLB | |
| SCHEMBL2557610 | 0.80 | SMN1; SMN2 (0.71) | ALDH1A1L3MBTL1SMN1; SMN2MAPK1TSHR | |
| SCHEMBL277495 | 0.80 | TDP1 (0.72) | ALDH1A1L3MBTL1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL2556186 | 0.80 | ALDH1A1 (0.76) | ALDH1A1SNCASMN1; SMN2MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED | 2009-11-12 | — | — | US | disclosed |
| EP-1348709-B1 | Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis | ASTRAZENECA UK LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
| EP-1222195-A1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025242-A1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | TYMS, DPYD, TYMP | ALDH1A1 307/4885L3MBTL1 4401/4885TDP1 244/4885 |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | TYMS, DPYD, TPMT | ALDH1A1 625/4885L3MBTL1 4430/4885TDP1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.